BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10634203)

  • 1. Drug resistance mutations among HIV-1 strains from antiretroviral-naive patients in Martinique, French West Indies.
    Césaire R; Dos Santos G; Abel S; Bera O; Sobesky G; Cabié A
    J Acquir Immune Defic Syndr; 1999 Dec; 22(4):401-5. PubMed ID: 10634203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
    J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patients.
    Fontaine E; Lambert C; Servais J; Ninove D; Plesséria JM; Staub T; Arendt V; Kirpach P; Robert I; Schneider F; Hemmer R; Schmit JC
    J Hum Virol; 1998; 1(7):451-6. PubMed ID: 10195266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
    Reinis M; Vandasová J; Stanková M; Linka M; Brůcková M
    Acta Virol; 2001; 45(5-6):279-86. PubMed ID: 12083326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy.
    Holodniy M; Mole L; Margolis D; Moss J; Dong H; Boyer E; Urdea M; Kolberg J; Eastman S
    J Virol; 1995 Jun; 69(6):3510-6. PubMed ID: 7745698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw cohort.
    Horban A; Stanczak JJ; Bakowska E; Tobolewska EJ; Przybylska-Stengiel KJ; Stanczak GP; Burkacka E
    Infection; 2002 Dec; 30(6):356-9. PubMed ID: 12478325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
    Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay.
    Wilson JW; Bean P; Robins T; Graziano F; Persing DH
    J Clin Microbiol; 2000 Aug; 38(8):3022-8. PubMed ID: 10921971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective vertical transmission of HIV-1 antiretroviral resistance mutations.
    Colgrove RC; Pitt J; Chung PH; Welles SL; Japour AJ
    AIDS; 1998 Dec; 12(17):2281-8. PubMed ID: 9863870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.
    Winters MA; Shafer RW; Jellinger RA; Mamtora G; Gingeras T; Merigan TC
    Antimicrob Agents Chemother; 1997 Apr; 41(4):757-62. PubMed ID: 9087484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
    Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
    AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.
    Frankel FA; Marchand B; Turner D; Götte M; Wainberg MA
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2657-64. PubMed ID: 15980333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid.
    Briones C; Pérez-Olmeda M; Rodríguez C; del Romero J; Hertogs K; Soriano V
    J Acquir Immune Defic Syndr; 2001 Feb; 26(2):145-50. PubMed ID: 11242181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.
    Yerly S; Rakik A; De Loes SK; Hirschel B; Descamps D; Brun-Vézinet F; Perrin L
    J Virol; 1998 May; 72(5):3520-3. PubMed ID: 9557630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.